A lot more than just saving blood
Blood is scarce and expensive. Additionally, current studies have shown that a blood transfusion is a risk factor for higher hospital mortality and numerous health complications.
For these reasons, and based on existing guidelines and evidence, patient blood management has been introduced at the University of Frankfurt Medical Center.
Three key measures aim at optimizing the use of donor blood transfusions:
- Special pre-treatment of high-risk patients before surgical procedures
- Minimization of blood loss during and after the operation
- Standardized test to determine whether a blood transfusion is actually reasonable
The usual practice of red blood cell (RBC) concentrate transfusion varies a lot throughout the world. With more than 50 transfused RBC concentrates per 1,000 inhabitants, Germany occupies the first place in Europe and worldwide as well (for comparison purposes, Australia has 36, the Netherlands 34; Norway 42; Great Britain 36; Switzerland 41). However, due to medical and societal changes, banked blood will become an increasingly scarce resource. A highly promising approach to a solution is the multidisciplinary patient blood management (PBM) concept, whose implementation is incidentally promoted by the World Health Organization (WHO) and presented below.
Diagnosis and therapy of preoperative anemia
According to WHO criteria, there is anemia when the hemoglobin value falls under 12 g/dl in women and under 13 g/dl in men. Musallam et al. report a 30% prevalence of preoperative anemia in an entire age group of 227,425 hospitalized patients. In the hospital, preoperative anemia is one of the strongest predictors for the administration of RBC concentrate during or after surgery. In addition, preoperative anemia must also be classified as stand-alone and independent risk factor for the occurrence of postoperative complications and higher postoperative mortality. In principle, every anemia should be clarified whenever possible before surgery and non-urgent procedures postponed until the respective anemia treatment has ended. A British study revealed that preoperative anemia correction in close collaboration with family physicians was able to reduce the incidence of preoperative anemia from 26% to 10% on the day of the operation and the risk for an intraoperative donor blood transfusion by more than half, from 26% to 13%. In German everyday situations, the cost of intravenous iron therapy, the separation of outpatient and inpatient care as well as the potential postponement of the procedure are the arguments often given against preoperative anemia treatment in a discussion. Compared to donor blood transfusions and apart from the cost and budgetary aspects, preoperative anemia treatment could also be worthwhile for the patients themselves (fewer transfusion-associated risks and side effects, better healing processes), for the hospital (patient recruiting and marketing) and for the general public as well (scarcity of banked blood, faster rehabilitation).
Minimization of unnecessary blood losses and protection of the body’s own reserves
Perioperative blood collection and procedural interventions could result in iatrogenic anemia. Thus, a weekly blood loss of up to 600 mL can occur in intensive care patients due to bloodwork alone. A current high estimate indicates an annual blood loss of 25 million liters of blood for the western world alone, taking current laboratory blood collection standards into account, and this inevitably leads to hospital-acquired anemia. Reducing the size of the small blood collection tubes and a daily strict indication can significantly reduce collection quantities and unnecessary blood losses without adversely affecting diagnostic quality.
Mechanized autotransfusion (MAT)
Technical aids like mechanized autotransfusion play an important role both during and after the operation. Starting with an estimated intraoperative blood loss of 0.5 – 1 liter, the preparation of the blood lost during surgery is regarded as reasonable as it has proven to lower the use of donor blood banks. Likewise, the use of MAT in tumor patients after previous irradiation of the blood lost during surgery or by using special leukocyte-depleting filters should be considered.
Perioperative management of anticoagulants
About 1 – 3% of the population receives anticoagulants permanently to prevent arterial and venous thromboembolisms or after a stent procedure. Depending on the indication, heparins, (direct) oral anticoagulants or thrombocyte aggregation inhibitors can be used here. A non-critical taking of the medications until the day of surgery would be accompanied by a very high hemorrhage risk. However, a general early discontinuation of the medication would be just as irresponsible because otherwise thromboembolisms or stent sealings would occur. Against this background, local standards for dealing perioperatively with anticoagulants should be laid down, e.g. as part of a patient blood management project.
Early individual risk stratification, e.g. in the anesthesia outpatient clinic, should consider the following factors: indication for anticoagulation – risk profile for thrombosis and hemorrhage, co-morbidity (kidneys, liver, bone marrow), co-medication (platelet aggregation inhibitors, non-steroidal anti-rheumatic drugs), urgency of the operation, regional anesthesia, hemorrhage risk owing to the planned operation (low/moderate/high) and the change of anticoagulation (bridging/switching).
Since various co-morbidities (e.g. impaired kidney and liver function) and co-medications (e.g. co-anticoagulants) can be associated with relevant hemorrhagic tendency in spite of a 2-fold half-life break in therapy, anticoagulation therapy with direct oral anticoagulants must be paused early in procedures with high bleeding risk in which a clinically significant hemorrhage cannot be ruled out (large abdominal operation, large vessel operation, large orthopedic operation, large intrathoracic surgical procedure, puncture of non-compressible vessels).
Intraoperative coagulation management
Appropriate and careful surgical bleeding control is the basis for prophylaxis and the efficient therapy of perioperative hemorrhages. Besides, basic physiological conditions like pH > 7.1, ionized calcium > 1.2 mmol/L and temperature > 36 °C are the basic prerequisites for optimal blood coagulation (hemostasis). If there is the slightest suspicion of hyperfibrinolysis, anti-hyperfibrinolytic drug therapy with tranexamic acid, for example, should be started. However, cell-mediated (primary) hemostasis can be improved with vasopressin analogs (desmopressin), for example. Any other follow-up therapy must build on this basic therapy, whereby the algorithm-based therapy of bleeding patients, in particular, allows effective and economical management. The primary objective of coagulopathy must be the causal therapy of the problem and not the symptomatic therapy with donor blood substitution.
Transfusion practice variability and transfusion-associated immunomodulation
Transfusion practice, especially with regard to the administration of RBC concentrate, varies a great deal in different countries and hospitals, which allows one to conclude that there is uncertainty concerning the appropriate indication and that possibly unneeded allogeneic blood products are being transfused. This large variability in the usual transfusion practice is all the more surprising because clear recommendations for dealing with blood products were expressed in Germany by the Cross-Sectional Guidelines of the German Medical Association. They recommend taking the criteria of the patient’s hemoglobin concentration, compensation ability and risk factor criteria into account.
Regarding the potential risks of RBC concentrate, the transfusion-associated transfers of bacteria, viruses, parasites or prions as well as not immune-mediated adverse drug effects (e.g. transfusion-associated volume overload, hypothermia, hyperkaliemia, citrate overload, transfusion hemosiderosis) are known.
In addition, the transfusion of cellular blood preparations, as “transplantation of the liquid organ blood” represent in fact an immunological challenge for the recipient organism too instead of blood group compatibility. The immune-mediated risks include:
Allergic transfusion reaction
Febrile non-hemolytic transfusion reaction
Transfusion-associated acute pulmonary insufficiency
Hemolytic transfusion reaction
Transfusion-associated graft vs. host disease
The long-term importance that is in store for the transfusion-associated immunomodulation is the subject of clinical research. Ultimately, RBC concentrate – like other medications with a relevant spectrum of adverse reactions – should be administered in an exclusively rational and medically indicated way. For example, by using a computerized requirement system for allogeneic RBC concentrate with a programmed decision algorithm based on guidelines and documenting the respective transfusion trigger in Stanford (USA), the share of RBC concentrate administrations that do not adhere to the guidelines were lowered from 66% to under 30% between 2009 and 2012 of all transfusions and the total quantity of RBC concentrate by 24%.
The main focus of a multimodal PBM is to protect and strengthen the patient’s own resources. This can be achieved by recognizing and treating anemia, meticulously minimizing perioperative blood loss, restricting diagnostic blood collections, having evidence-based coagulation and hemotherapy concepts as well as a guideline-compliant, rational indication of RBC concentrate. The effects of a PBM concept on German hospitals is being scientifically investigated in multiple centers.
Patient Blood Management helps to save blood
Patient blood management (PBM) was introduced at the University of Frankfurt Medical Center in July 2013 in order to protect and exploit the patient’s own blood resources. Moreover, during and after the operation, more blood-saving work is being performed than ever before: During the organization, it is ensured that the patient’s blood coagulation is working well and the blood lost in surgery is prepared for its return. For its dedication, the hospital received the 2016 Patient Safety Prize, awarded annually by the Patient Safety Active Group. The Aesculap Academy in Tuttlingen is one of the prize sponsors. Patient blood management allows doctors to reduce the need for blood transfusions by ten percent, thereby lowering the risk of acute kidney damage for the operated person and also the costs involved. A study conducted with 130,000 patients has proven the benefits for patients. Already more than 100 hospitals across Germany are working on the introduction of the PBM concept.